Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

Fig. 3

Systolic function (ΔdP/dtmax) in supply ischemia protocol. Mean ± SEM. There were no statistically significant differences between groups at BO1. At BL2, dP/dtmax for GLP-1 was significantly improved compared to control (p = 0.02) and compared to glibenclamide alone (p < 0.01). This difference was maintained for comparison with control at BO2 (p = 0.02) and was numerically better than glibenclamide at BO2 (p = 0.12). dP/dtmax for GLP-1 + glibenclamide was significantly improved at BL2 compared to control (p = 0.02) and glibenclamide alone (p = 0.03). Again this difference was maintained for comparison with control at BO2 (p = 0.02) and trended towards improvement for glibenclamide alone at BO2 (p = 0.14). There was no statistically significant difference between GLP-1 treated groups, nor any difference between the control and glibenclamide only groups, at any timepoint

Back to article page